March 05, 2003

LESLIE J. WILLIAMS JOINS BATTELLEPHARMA AS VICE PRESIDENT, COMMERCIAL DEVELOPMENT

BattellePharma Media Contact:
Christy Polsley-Finch
(614) 340-2361
finch@battellepharma.com

COLUMBUS, Ohio - BattellePharma, a privately-held specialty pharmaceutical company, announced today that Leslie J. Williams will join the BattellePharma executive team as Vice President, Commercial Development effective March 17.

Williams, who most recently held the position of Director of Marketing for INO Therapeutics, Inc., brings more than 13 years' experience in marketing and commercial development in the pharmaceutical industry to BattellePharma. While at INO Therapeutics, Williams assisted R&D with the development of the NDA submission for INOmax® (nitric oxide) for inhalation. Williams was responsible for the commercial aspects of INOmax® including establishing the U.S. commercial objectives for the product, setting marketing objectives and strategy, expanding the commercial organization, developing key constituency groups and expert advisory boards, and overseeing the launch of the INOtherapy® platform. The INOtherapy^TM platform includes INOmax (nitric oxide) for inhalation, the INOvent® delivery system, and the INOcal calibration gases and services. Since the launch of INOtherapy® in 2000, the product has achieved nearly $100 million in annual revenues.

"We are very fortunate to attract an individual with Leslie Williams' expertise to head up our commercial development function," said Chuck Bramlage, BattellePharma President and CEO. "Leslie's proven track record of managing successful commercial products and her understanding of delivery systems will be a tremendous asset to us as we progress the development of our own Mystic^TMasthma compound."

"I am delighted to join BattellePharma and look forward to contributing to the development and commercialization of its exciting technologies," stated Leslie Williams.

Williams holds a MBA from Washington University, John Olin School of Business and a B.S. Degree in Nursing from the University of Iowa. Williams joined INO Therapeutics, Inc., in 1996, where she held a series of commercial positions including: Critical Care Specialist and Project Manager, Eastern Regional Sales Manager, Director of Sales, and her most recent position of Director of Marketing. Williams also has prior pharmaceutical commercial experience with Merck and GlaxoSmithKline.

About BattellePharma

BattellePharma is a privately-held specialty pharmaceutical company leveraging science and technology to design more effective medicines. BattellePharma's products are based on two platform technologies: Mystic inhalation technology and novel formulation technologies. The company develops products by combining these platforms with novel or generic compounds to create therapies to treat respiratory and systemic diseases. BattellePharma's MysticTM technology is expected to set a new standard for inhaled drug delivery in the 21st century. BattellePharma has partnerships with numerous pharmaceutical corporations including Abbott Laboratories, Corus Pharma Inc., GlaxoSmithKline, Pfizer Inc., Pharmacia Corporation, and VIASYS Healthcare GmbH. For more information on BattellePharma, reference the company's website at www.battellepharma.com.